People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...